BR112016013502A2 - unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol. - Google Patents

unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.

Info

Publication number: BR112016013502A2
Authority: BR; Brazil
Prior art keywords: dosage unit; solid dosage; unit containing; orally disintegrating; disintegrating solid
Prior art date: 2013-12-12

Application number

BR112016013502A

Other languages

English (en)

Other versions

BR112016013502B1 (pt

Inventor

Jan Tijmen Coelingh Bennink Herman

Jan Platteeuw Johannes

Original Assignee

Donesta Bioscience B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-12

Filing date

2014-12-10

Publication date

2018-07-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016013502(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-10 Application filed by Donesta Bioscience B V filed Critical Donesta Bioscience B V

2018-07-03 Publication of BR112016013502A2 publication Critical patent/BR112016013502A2/pt

2021-05-11 Publication of BR112016013502B1 publication Critical patent/BR112016013502B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Zoology (AREA)
Nutrition Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BR112016013502-4A 2013-12-12 2014-12-10 unidade de dosagem farmacêutica sólida que desintegra oralmente contendo um componente de estetrol, método para a preparação da unidade de dosagem sólida e uso de grânulos consistindo em um componente de estetrol BR112016013502B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP13196904.0		2013-12-12
EP13196904		2013-12-12
PCT/EP2014/077127 WO2015086643A1 (en)	2013-12-12	2014-12-10	Orally disintegrating solid dosage unit containing an estetrol component

Publications (2)

Publication Number	Publication Date
BR112016013502A2 true BR112016013502A2 (pt)	2018-07-03
BR112016013502B1 BR112016013502B1 (pt)	2021-05-11

Family

ID=49759137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112016013502-4A BR112016013502B1 (pt)	2013-12-12	2014-12-10	unidade de dosagem farmacêutica sólida que desintegra oralmente contendo um componente de estetrol, método para a preparação da unidade de dosagem sólida e uso de grânulos consistindo em um componente de estetrol

Country Status (29)

Country	Link
US (2)	US9884064B2 (pt)
EP (1)	EP3079671B1 (pt)
JP (1)	JP6447931B2 (pt)
KR (1)	KR102265150B1 (pt)
CN (1)	CN105979935B (pt)
AU (1)	AU2014363599B2 (pt)
BR (1)	BR112016013502B1 (pt)
CA (1)	CA2932855C (pt)
CL (1)	CL2016001411A1 (pt)
CY (1)	CY1119817T1 (pt)
DK (1)	DK3079671T3 (pt)
EA (1)	EA032306B1 (pt)
ES (1)	ES2655076T3 (pt)
HR (1)	HRP20180129T1 (pt)
HU (1)	HUE035848T2 (pt)
IL (1)	IL246082B (pt)
LT (1)	LT3079671T (pt)
MA (1)	MA39105B1 (pt)
MX (1)	MX369035B (pt)
NO (1)	NO3079671T3 (pt)
NZ (1)	NZ720906A (pt)
PL (1)	PL3079671T3 (pt)
PT (1)	PT3079671T (pt)
RS (1)	RS56738B1 (pt)
SG (1)	SG11201604741UA (pt)
SI (1)	SI3079671T1 (pt)
TN (1)	TN2016000230A1 (pt)
WO (1)	WO2015086643A1 (pt)
ZA (1)	ZA201603903B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012164096A1 (en)	2011-06-01	2012-12-06	Estetra S.A.	Process for the production of estetrol intermediates
US11053273B2 (en)	2011-06-01	2021-07-06	Estetra S.P.R.L.	Process for the production of estetrol intermediates
EP2383279A1 (en)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Process for the preparation of estetrol
AU2012293593B2 (en) *	2011-08-11	2017-03-23	Estetra Srl	Use of estetrol as emergency contraceptive
DK3310345T3 (da)	2015-06-18	2021-05-25	Estetra Sprl	Orodispersibel tablet indeholdende estetrol
CR20180041A (es) *	2015-06-18	2018-05-03	Mithra Pharmaceuticals S A	Unidad de dosificación orodispersable que contiene un componente estetrol.
LT3310346T (lt)	2015-06-18	2021-06-10	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
JP6863547B2 (ja)	2015-06-18	2021-04-21	エステトラソシエテプリーヴアレスポンサビリテリミテ	エステトロール成分を含有する口腔内崩壊性投与単位
US20200046729A1 (en) *	2016-08-05	2020-02-13	Estetra Sprl	Methods using combined oral contraceptive compositions with reduced cardiovascular effects
CA3178291A1 (en)	2016-08-05	2018-04-12	Estetra Srl	Method for the management of dysmenorrhea and menstrual pain
JP2021513507A (ja) *	2018-02-07	2021-05-27	エステトラソシエテプリーヴアレスポンサビリテリミテ	心臓血管系への影響を低減した避妊薬組成物
TWI801561B (zh) *	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar)	2018-04-19	2019-10-19	Estetra Sprl	مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu)	2019-09-03	2022-04-28	Richter Gedeon Nyrt.	Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
WO2024160373A1 (en)	2023-02-02	2024-08-08	Industriale Chimica S.R.L.	PROCESS FOR PREPARING (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRATE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997004752A1 (en) *	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en)	1999-01-26	2000-09-12	Place; Virgil A.	Drug dosage unit for buccal administration of steroidal active agents
WO2002094276A1 (en) *	2001-05-18	2002-11-28	Pantarhei Bioscience B.V.	Pharmaceutical composition for use in hormone replacement therapy
EP1260225A1 (en)	2001-05-18	2002-11-27	Pantarhei Bioscience B.V.	A pharmaceutical composition for use in hormone replacement therapy
EP1390041B1 (en) *	2001-05-23	2009-11-25	Pantarhei Bioscience B.V.	Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2002094279A1 (en)	2001-05-23	2002-11-28	Pantarhei Bioscience B.V.	Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
WO2003018026A1 (en)	2001-08-31	2003-03-06	Pantarhei Bioscience B.V.	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003041718A1 (en)	2001-11-15	2003-05-22	Pantarhei Bioscience B.V.	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
EA007599B1 (ru) *	2002-02-21	2006-12-29	Шеринг Акциенгезельшафт	Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в
GB0410616D0 (en)	2004-05-13	2004-06-16	Unilever Plc	Antiperspirant or deodorant compositions
US20070048369A1 (en)	2005-08-26	2007-03-01	National Starch And Chemical Investment Holding Corporation	Mucosal delivery tablet
US20090221540A1 (en)	2006-01-09	2009-09-03	Pantarhei Bioscience B.V.	Method of Treating An Acute Vascular Disorder
US20070286819A1 (en)	2006-06-08	2007-12-13	Warner Chilcott Company, Inc.	Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
ES2659316T3 (es) *	2006-06-08	2018-03-14	Allergan Pharmaceuticals International Limited	Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada
AR064014A1 (es) *	2006-11-29	2009-03-04	Wyeth Corp	Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
EP2124900B1 (en) *	2006-12-20	2014-12-03	Teva Women's Health, Inc.	Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
AR064875A1 (es) *	2007-01-12	2009-04-29	Wyeth Corp	Composiciones de tableta en tableta
US8367647B2 (en)	2007-06-21	2013-02-05	Pantarhei Bioscience B.V.	Treatment of meconium aspiration syndrome with estrogens
WO2010033832A2 (en)	2008-09-19	2010-03-25	Evestra, Inc.	Estriol formulations
DE102009007771B4 (de) *	2009-02-05	2012-02-16	Bayer Schering Pharma Aktiengesellschaft	Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102058604A (zh) *	2009-11-17	2011-05-18	北京万全阳光医学技术有限公司	一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
WO2014159377A1 (en)	2013-03-14	2014-10-02	Teva Women's Health, Inc.	Compositions containing tanaproget and natural estrogens

2014
- 2014-12-10 NZ NZ720906A patent/NZ720906A/en unknown
- 2014-12-10 NO NO14814804A patent/NO3079671T3/no unknown
- 2014-12-10 CA CA2932855A patent/CA2932855C/en active Active
- 2014-12-10 BR BR112016013502-4A patent/BR112016013502B1/pt not_active IP Right Cessation
- 2014-12-10 SG SG11201604741UA patent/SG11201604741UA/en unknown
- 2014-12-10 EA EA201691226A patent/EA032306B1/ru unknown
- 2014-12-10 WO PCT/EP2014/077127 patent/WO2015086643A1/en active Application Filing
- 2014-12-10 CN CN201480075244.4A patent/CN105979935B/zh active Active
- 2014-12-10 LT LTEP14814804.2T patent/LT3079671T/lt unknown
- 2014-12-10 PT PT148148042T patent/PT3079671T/pt unknown
- 2014-12-10 SI SI201430525T patent/SI3079671T1/en unknown
- 2014-12-10 KR KR1020167018146A patent/KR102265150B1/ko active IP Right Grant
- 2014-12-10 EP EP14814804.2A patent/EP3079671B1/en active Active
- 2014-12-10 TN TN2016000230A patent/TN2016000230A1/en unknown
- 2014-12-10 HU HUE14814804A patent/HUE035848T2/en unknown
- 2014-12-10 RS RS20180016A patent/RS56738B1/sr unknown
- 2014-12-10 DK DK14814804.2T patent/DK3079671T3/en active
- 2014-12-10 MA MA39105A patent/MA39105B1/fr unknown
- 2014-12-10 US US15/103,180 patent/US9884064B2/en active Active
- 2014-12-10 PL PL14814804T patent/PL3079671T3/pl unknown
- 2014-12-10 JP JP2016539161A patent/JP6447931B2/ja active Active
- 2014-12-10 MX MX2016007595A patent/MX369035B/es active IP Right Grant
- 2014-12-10 ES ES14814804.2T patent/ES2655076T3/es active Active
- 2014-12-10 AU AU2014363599A patent/AU2014363599B2/en active Active
2016
- 2016-06-07 IL IL246082A patent/IL246082B/en active IP Right Grant
- 2016-06-08 CL CL2016001411A patent/CL2016001411A1/es unknown
- 2016-06-08 ZA ZA2016/03903A patent/ZA201603903B/en unknown
2017
- 2017-12-22 US US15/852,187 patent/US9987287B2/en active Active
2018
- 2018-01-10 CY CY20181100031T patent/CY1119817T1/el unknown
- 2018-01-23 HR HRP20180129TT patent/HRP20180129T1/hr unknown

Also Published As

Publication number	Publication date
WO2015086643A1 (en)	2015-06-18
CY1119817T1 (el)	2018-06-27
HRP20180129T1 (hr)	2018-02-23
MA39105A1 (fr)	2017-04-28
JP2016540021A (ja)	2016-12-22
US9987287B2 (en)	2018-06-05
US9884064B2 (en)	2018-02-06
LT3079671T (lt)	2018-02-12
ES2655076T3 (es)	2018-02-16
KR20160102212A (ko)	2016-08-29
IL246082A0 (en)	2016-07-31
AU2014363599B2 (en)	2019-10-31
AU2014363599A1 (en)	2016-06-30
TN2016000230A1 (en)	2017-10-06
KR102265150B1 (ko)	2021-06-16
NO3079671T3 (pt)	2018-03-24
EP3079671A1 (en)	2016-10-19
PT3079671T (pt)	2017-11-24
MA39105B1 (fr)	2018-05-31
CA2932855A1 (en)	2015-06-18
RS56738B1 (sr)	2018-03-30
PL3079671T3 (pl)	2018-03-30
HUE035848T2 (en)	2018-05-28
BR112016013502B1 (pt)	2021-05-11
EA201691226A1 (ru)	2016-10-31
CN105979935B (zh)	2019-07-26
CL2016001411A1 (es)	2016-11-11
SI3079671T1 (en)	2018-04-30
US20180117063A1 (en)	2018-05-03
EA032306B1 (ru)	2019-05-31
IL246082B (en)	2018-03-29
JP6447931B2 (ja)	2019-01-09
MX369035B (es)	2019-10-25
ZA201603903B (en)	2018-07-25
US20160310506A1 (en)	2016-10-27
DK3079671T3 (en)	2017-12-11
NZ720906A (en)	2022-04-29
MX2016007595A (es)	2016-11-28
CN105979935A (zh)	2016-09-28
SG11201604741UA (en)	2016-07-28
CA2932855C (en)	2022-07-19
EP3079671B1 (en)	2017-10-25

Publication	Publication Date	Title
BR112016013502A2 (pt)	2018-07-03	unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.
DK3701944T3 (da)	2022-03-14	Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
DK3229810T3 (da)	2020-08-17	Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
HK1223825A1 (zh)	2017-08-11	包含阿曲生坦的穩定化藥物劑型
BR112015031478A2 (pt)	2017-07-25	dispositivo de contenção de poço
HK1223833A1 (zh)	2017-08-11	藥物劑型
CL2015002389A1 (es)	2016-08-26	Composiciones herbicidas que contienen isoxabena y flufenaceto.
FR3008610B1 (fr)	2018-03-30	Dispositif doseur de particules.
TH1401006819B (th)	2016-03-04	สูตรน้ำในน้ำมัน (W/O) ของสารฆ่าแมลง (Inseticidal water-in-oil (W/O) formulation)
DK3071261T3 (da)	2019-07-29	Lægemiddeladministrationsanordning
FR3008854B1 (fr)	2016-01-01	Sous-vetement de contention
UA27481S (uk)	2014-07-25	Сантехнічний змішувач для кухні (фенікс мх7111020с-15cm)
ES1078951Y (es)	2013-07-08	Cajon flamenco
TH1501002956A (th)	2016-09-08	สถาปัตยกรรมระบบของส่วนต่อประสานกับผู้ใช้สำหรับตัวจ่ายเชื้อเพลิง
ITAN20130115A1 (it)	2014-09-06	Faretra odontoiatrica perfezionata.
TH1501000860A (th)	2016-08-01	สิ่งเตรียมทางเภสัชกรรมชนิดของแข็งที่มีลีไวไธโรซีน
ES1103857Y (es)	2014-06-10	Funda para instrumento oftalmologico
FR3012436B1 (fr)	2015-12-11	Dispositif de deversement de dechets formant garde-corps.
ES1078938Y (es)	2013-07-01	Dispositivo de seguimiento de cajones paletizables.
UA26239S (uk)	2014-01-10	Пробка
TH1501000527B (th)	2016-03-23	จุกอุดรู
UA25504S (uk)	2013-09-25	Пробка
CL2014000235S1 (es)	2014-08-29	Sanitario
UA25141S (uk)	2013-07-10	Пробка
UA25143S (uk)	2013-07-10	Пробка

Legal Events

Date	Code	Title	Description
2018-07-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-10-01	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-06-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-07-14	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-12-15	B25A	Requested transfer of rights approved	Owner name: ESTETRA SPRL (BE)
2021-03-02	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-05-11	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/12/2014, OBSERVADAS AS CONDICOES LEGAIS.
2022-10-25	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 8A ANUIDADE.
2023-02-14	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.